Presentation Title: Nanotechnology via the Control of Bioprocesses with Nanostructured Inorganics
Prof. Galen Stucky presented this talk in the webinar on Nanomedicine, Nanomaterials and Nanotechnology organized by Vebleo
Authors:
Galen Stucky1, Damien Kudela2, James Morrissey3, Stephanie Smith3, April M. Sawvel4, Sarah E. Baker4, Todd A. Ostomel5, Jie Fan6, Chi Nguyen7, Anna May-Masnou8
Affiliation:
1University of California, Santa Barbara CA 93106 USA
2Cayuga Biotech, Bridgewater NJ 08807, USA
3University of Michigan, Ann Arbor MI 48109 USA
4Lawrence Livermore National Laboratory, Livermore CA 94551 USA
5Squire Patton Boggs, Palo Alto CA 94301 USA
6Zhejiang University, Hangzhou 310027 China
7United States Military Academy, West Point NY 10996 USA
8ICMAB-CSIC, Barcelona 08193 Spain
Biography
Galen Stucky obtained his Ph.D. degree in Physical Chemistry with Robert E. Rundle at Iowa State University in 1962. At the University of California, Santa Barbara (UCSB), he is a Professor in the Department of Chemistry & Biochemistry and in the Materials Department and is a member of the interdepartmental graduate program in Biomolecular Science and Engineering.
Prof. Galen Stucky currently holds the UCSB Khashoggi Chair in Materials Chemistry. Before coming to UCSB in 1985, he was on the faculty of the University of Illinois at Urbana-Champaign, where he was promoted to Full Professor in 1972, and was a research group leader at Sandia National Laboratory and at DuPont Central Research and Development.
Prof. Galen Stucky ‘s honors include a von Humboldt Senior US Scientist award (2000), the American Chemical Society Award in the Chemistry of Materials (2002), the International Mesostructured Materials Association Award (2004), election to fellowship in the American Academy of Arts and Sciences (2005), the Advanced Technology Applications for Combat Casualty Care Award (2008), election the US National Academy of Sciences (2013), and the Prince of Asturias Award for Technical and Scientific Research, with A. Corma and M. E. Davis (2014).
Prof. Galen Stucky has published over 800 refereed scientific articles and has been awarded 37 U. S. patents. In Prof. Galen Stucky ’s current research, the overall goal is the design and synthesis of new materials with an emphasis on understanding interface and nucleation chemistry and creating multifunctional 3-D systems by cooperative molecular assembly, including the use of nanostructured nanoparticles and 3-D surfaces to direct biosystem processes.
Abstract
This talk will give an overview of our efforts to develop simple, low-cost inorganic remedial agents, for point-of-care therapeutic treatment and control of the external arterial and the internal bleeding that results from traumatic injuries. The nanostructured inorganic material agents were considered as systems, defined by their physical properties, including surface charge, pH-dependent isoelectric point in simulated body fluid (SBF), heat of reaction in SBF, electrolyte delivery, surface area, porosity, nanoparticle morphology and size, and acid-base properties.
The goal has been to determine how these properties might be selectively used to control external and internal bleeding as it is defined by the blood-clotting system. The blood-clotting biosystem is self-regulating using clotting as well as anti-clotting to localize the clotting activity, and the therapeutic agent must be consonant with that regulation. The experimental procedures that were used began by in vitro testing of blood coagulation for a variety of property-defined nanostructured inorganic material systems as determined by in vitro thromboelastograph measurements using whole and factor-deficient blood plasma.
The research was sponsored by invitation from medical scientists of the United States Office of Naval Research (ONR) during the early stages of the Iraq war. Shelf life, stability, and usability in extreme environments were key requirements along with the figure of merit of stopping major external arterial bleeding in a few minutes of its initiation.
The experimental in vitro results obtained at UCSB were validated by ONR researchers, and, when promising, for external arterial bleeding by in vivo hemostasis testing with large animals by the ONR medical center. If that result was a statistical improvement over the best currently used in practice, the agent was commercially packaged and sent to Iraq for “clinical” trial, the results of which were shared with our lab and were used to improve the performance of the inorganic agent for the hemostasis of major arterial bleeding.
The best agent was approved by the FDA for civilian use in the United States in 2012, is currently (2019) the preferred agent for external arterial bleeding hemostasis for all branches of the US uniformed services, and is widely used by civilian first responders.
The targeting and therapeutic treatment of internal bleeding must address a longer time scale and be inclusive of venous, capillary, and arterial bleeding. A strategy for doing this was developed in a co-PI project by James Morrisey (U. Michigan) and UCSB. The targeting is done using short-chain polyphosphate functionalized silica nanoparticles, which can be safely administered via the cardiovascular network of the body, without inducing coagulation in normal blood. The nanoparticle target is the common pathway of the blood-clotting cascade system, which is normally activated at a bleeding site by short-chain polyphosphate oligomers that are released by blood platelets at the trauma site.
Graphical Abstract
This talk was delivered in the webinar organized by Vebleo